First-line treatment with a combination of Yervoy (ipilimumab) and Keytruda (pembrolizumab) failed to prolong survival and delay disease progression in patients with advanced non-small cell lung cancer (NSCLC) compared with Keytruda alone, according to data from a Phase 3 trial. The KEYNOTE-598 (NCT03302234) trial involved patients whose tumors produced high levels of PD-L1 and harbored…
About Cancer
Cancer, also called malignancy, is an abnormal growth of cells with the potential to invade or spread to surrounding tissues and structures found within the body. There are more than 100 types of cancer. A few examples include breast cancer, skin cancer, lung cancer, colon cancer, prostate cancer, and lymphoma. According to the American Cancer Society, 4 out of 10 people will be diagnosed with some form of cancer in their lifetime. Cancer prevalence has given rise to multiple medical specialties focused on symptom management and disease management. Current treatment options depending on the form of cancer include chemotherapy, radiation, blood or bone marrow transfusions, and/or surgery. Lifetime prognosis of cancer mortality is dependent on the type of cancer and is heavily conditional to early detection.
Conditions
Cancer News
‘Overwhelmingly Positive’ Data Halts Endoxifen Phase 2 Trial for Invasive Cancer
After promising results from patients enrolled to date, Atossa Therapeutics halted an Australian Phase 2 clinical trial evaluating its investigative oral therapy Endoxifen in women newly diagnosed with invasive, estrogen receptor (ER)-positive breast cancer and scheduled for surgery. “It is a welcome event to halt an ongoing clinical trial because the results are so overwhelmingly…
Phase 3 Trial of ATG-010 (Xpovio) for Advanced Myeloma Opens in China
China’s regulatory agency has approved the start of a Phase 3 clinical trial testing ATG-010 (selinexor), in combination with Velcade (bortezomib) and dexamethasone, in multiple myeloma patients after one to three prior lines of treatment. The trial will include about 150 patients in China with relapsed of refractory multiple myeloma, and randomly assign them to the…
Cytovia, NCI Team Up to Develop CAR NK-cell Therapy for Solid Tumors
Cytovia Therapeutics has entered into a licensing agreement with the National Cancer Institute (NCI) to develop a new “off-the-shelf” immunotherapy for solid tumors. The immunotherapy is based on “natural killer” or NK immune cells, which have been genetically modified to produce a chimeric antigen receptor, or CAR, that targets a specific cancer protein, Cytovia said…
Dosing Begins in Phase 1 Trial of FT-7051 for Advanced, Resistant Cancer
Dosing has begun in a Phase 1 clinical trial testing Forma Therapeutics’ investigational therapy FT-7051 in people with metastatic castration-resistant prostate cancer (mCRPC). Recruiting at sites in Arizona and South Carolina, the open-label trial (NCT04575766) is expected to enroll 45 patients who failed to respond to at least one potent anti-androgen treatment. Contact and site information…
Early Trial Starts Testing Recommended STRO-002 Dose for Advanced Cancer
Sutro Biopharma‘s Phase 1 clinical trial has begun testing the recommended dose of STRO-002 in heavily pretreated patients with advanced ovarian cancer. “We are excited to be part of the STRO-002-GM1 dose-expansion study and to provide additional clinical data to show the potential of this therapeutic for ovarian patients with limited treatment options,” Lainie Martin, MD,…
Theralink Begins Testing New Biomarker Assay for Breast Cancer Tumors
Theralink Technologies announced that it has begun testing its new profiling biomarker assay — a test that could potentially provide oncologists with key information about a patient’s specific tumor — in people with breast cancer. “The Theralink assay for breast cancer may reveal therapeutic options for oncologists and in turn, may provide better outcomes for…
Blocking Glutamine Metabolism May Help Combat OCCC Tumors
Ovarian cancer cells harboring mutations in the ARID1A tumor suppressor gene tend to use the amino acid glutamine as a source of energy more often, making the cells more vulnerable to compounds that interfere with glutamine metabolism, scientists found. As proof, they demonstrated that a compound that inactivates glutaminase (the enzyme that normally breaks down…
EMA Plans Speedy Review of Cilta-cel, CAR T-cell Therapy for Advanced Myeloma
An accelerated review will be given an application for European Union approval of ciltacabtagene autoleucel (cilta-cel), a potential CAR T-cell therapy for heavily pre-treated multiple myeloma patients, its developer, Janssen, announced. An accelerated assessment, given to medications expected to have a major impact on public health, shortens the regulatory review process in Europe to 150 days from the…
Keytruda Closer to Expanded EU Approval for Resistant Hodgkin’s Lymphoma
Keytruda (pembrolizumab) has been recommended for approval in the European Union (EU) to treat adults and children, 3 years and older, with relapsed or refractory classical Hodgkin’s lymphoma (cHL) whose disease failed to respond to autologous stem cell transplant (ASCT) or who received at least two prior therapies when ineligible for ASCT. The therapy is…
NBA Teams Join Efforts to Raise Money and Awareness
The Prostate Cancer Foundation (PCF) and several NBA teams are joining efforts to raise money and awareness for prostate cancer research throughout February. Various national basketball teams, including the Atlanta Hawks, Chicago Bulls, and Phoenix Suns, are taking part in the Third Annual PCF Black History Month Assist Challenge. “We are thrilled and honored that…
First Glioblastoma Patient Dosed in Phase 2 Trial Testing PVSRIPO Plus Keytruda
The first patient has been dosed in a Phase 2 trial assessing the safety and preliminary efficacy of PVSRIPO in combination with Keytruda (pembrolizumab) as a treatment for people with recurrent glioblastoma multiforme (rGBM), an aggressive form of brain cancer. The open-label study, called LUMINOS-101 (NCT04479241), aims to enroll around 30 adults with rGBM from several…